NT219, a novel agent designed to overcome tumor resistance to drug therapy, will be evaluated in combination with the ...

Signs an Amended & Restated License Agreement for Multiple Technologies for Gene Therapy for Type 1 and Type 2 Diabetes Forms a Wholl ...

KL Deemed to be University is happy to announce that Lakshmi Soumya Emani, a Ph.D. scholar in Biotechnology, has earned the ...

Illinois is investing millions to foster tech innovation. Find out how this new program is connecting startups with ...

Purple Biotech (PPBT) is advancing into a Phase 2 study with NT219 in patients with recurrent/metastatic squamous cell carcinoma of the head ...

Genprex (GNPX) announced the advancement of its diabetes gene therapy program, including its relationship and collaboration with the University ...

The NIH says funding cuts would save it billions of dollars a year. D.C.-area industry and academic leaders say it would cripple R&D.

NT219, a novel agent designed to overcome tumor resistance to drug therapy, will be evaluated in combination with the standard-of-care head and neck cancer drugs pembrolizumab (Keytruda) or cetuximab ...

First patient dosed in the pediatric cohort of the Phase 1/2 trial of OPGx-LCA5; initial data on the cohort anticipated by Q3 ...

Amity University Madhya Pradesh hosted its Convocation Ceremony for its class of 2024 in a grand and dignified atmosphere, on ...

Governor JB Pritzker and the Illinois Department of Commerce and Economic Opportunity (DCEO) announced 35 awards totaling ...